Tech’s Merlin CP-GEP Test Secures FDA Breakthrough Device Designation
TECH•Tech’s Merlin CP-GEP test for early-stage melanoma metastasis was granted FDA Breakthrough Device designation on July 1, enabling priority review and interactive agency feedback. The designation accelerates potential U.S. market entry for the integrated gene expression and clinicopathologic classifier, bolstering Tech’s oncology diagnostics pipeline.
1. FDA Breakthrough Device Designation
Merlin CP-GEP, Tech’s combined gene expression and clinicopathologic classifier for assessing early-stage melanoma metastasis risk, received FDA Breakthrough Device designation on July 1, granting priority review and enhanced interaction with regulators.
2. Accelerated Approval and Market Entry
The designation allows Tech to pursue an expedited premarket approval pathway, potentially shortening U.S. regulatory timelines and supporting a targeted commercial launch for Merlin CP-GEP in 2027.
3. Strategic and Commercial Outlook
This milestone strengthens Tech’s position in the oncology diagnostics market by highlighting its integrated risk-assessment approach and could facilitate new partnerships, reimbursement discussions, and revenue growth.
